Wilson Sonsini Goodrich & Rosati has invested in genomic sequencing amplification business Bioskryb, co-founded by Stanford faculty member Charles Gawad.
Bioskryb, a US-based genomic sequencing amplification technology developer, has collected $11.5m in a seed round led by venture capital firm Anzu Partners.
Law firm Wilson Sonsini Goodrich & Rosati also contributed to the seed round.
Founded in 2018, Bioskryb is developing technologies that amplify existing gene sequencing systems so researchers can model near-complete genomes of the DNA in single cells using limited samples.
Bioskryb’s technology is principally tailored to cancer single-cell genomics and bacterial genomics. It builds on research by Charles Gawad, a clinical instructor in the haematology and oncology branch of Stanford’s paediatric unit.
The funding will go to product development in the translational research and clinical diagnostics spaces centred around both genomic and transcriptomic applications, with the latter encompassing studies of whole RNA structures.
